Jeil Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Jeil Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has a cash flow conversion efficiency ratio of -0.037x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.47 Billion ≈ $-6.42 Million USD) by net assets (₩253.26 Billion ≈ $171.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jeil Pharmaceutical Co Ltd (2017–2025)
Cash flow conversion efficiency of Jeil Pharmaceutical Co Ltd from 2017 to 2025. This chart illustrates how Jeil Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 271980 live share price for real-time trading data and today's change.
Jeil Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Jeil Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jeil Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see 271980 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BingEx Ltd
NASDAQ:FLX
|
0.126x |
|
Tropical Canning (Thailand) Public Company Limited
BK:TC
|
0.041x |
|
Shotspotter Inc
NASDAQ:SSTI
|
0.062x |
|
Carlo Gavazzi Holding AG
SW:GAV
|
0.020x |
|
Enablence Technologies Inc
V:ENA
|
0.077x |
|
Stella Holdings Bhd
KLSE:5006
|
-0.150x |
|
Lotte Himart
KO:071840
|
0.087x |
|
Brii Biosciences Limited
F:7SS
|
N/A |
Annual Cash Flow Conversion Efficiency for Jeil Pharmaceutical Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Jeil Pharmaceutical Co Ltd from 2017 to 2025. Review free cash flow generation of Jeil Pharmaceutical Co Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩251.03 Billion ≈ $170.12 Million |
₩-5.69 Billion ≈ $-3.86 Million |
-0.023x | -254.72% |
| 2024-12-31 | ₩219.32 Billion ≈ $148.63 Million |
₩3.21 Billion ≈ $2.18 Million |
0.015x | +146.19% |
| 2023-12-31 | ₩157.03 Billion ≈ $106.42 Million |
₩-4.98 Billion ≈ $-3.38 Million |
-0.032x | +67.42% |
| 2022-12-31 | ₩155.60 Billion ≈ $105.45 Million |
₩-15.15 Billion ≈ $-10.26 Million |
-0.097x | -185.29% |
| 2021-12-31 | ₩167.35 Billion ≈ $113.41 Million |
₩19.10 Billion ≈ $12.94 Million |
0.114x | +203.36% |
| 2020-12-31 | ₩172.48 Billion ≈ $116.89 Million |
₩-19.05 Billion ≈ $-12.91 Million |
-0.110x | -164.84% |
| 2019-12-31 | ₩170.04 Billion ≈ $115.24 Million |
₩28.96 Billion ≈ $19.62 Million |
0.170x | +46.80% |
| 2018-12-31 | ₩184.93 Billion ≈ $125.33 Million |
₩21.45 Billion ≈ $14.54 Million |
0.116x | +590.46% |
| 2017-12-31 | ₩177.99 Billion ≈ $120.62 Million |
₩-4.21 Billion ≈ $-2.85 Million |
-0.024x | -- |
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more